The Shared Neuropeptide: CGRP
Migraine is not simply a headache. It is a neurovascular event driven by the trigeminal nerve releasing calcitonin gene-related peptide (CGRP) — a potent vasodilator — into the meningeal blood vessels. This causes the characteristic pulsating, pressure-like pain. What is less widely understood is that CGRP is also expressed in the sensory nerve fibres of the scalp, where it drives neurogenic inflammation in response to stress, heat, and mechanical loading.
The scalp and the meninges share a common neurochemical language. Interventions that suppress peripheral CGRP release — including occipital nerve compression, vagal stimulation, and parasympathetic activation — operate upstream of migraine itself.
Non-Invasive Vagus Nerve Stimulation: From Device to Protocol
The FDA has approved two indications for non-invasive vagus nerve stimulation (nVNS):
- Acute treatment of episodic cluster headache (2018)
- Preventive treatment of episodic migraine (2019)
The approved device, gammaCore, delivers electrical stimulation to the cervical vagus nerve at the neck. The mechanism: vagal afferents activate the noradrenergic locus coeruleus, which in turn suppresses CGRP release from trigeminal terminals and restores parasympathetic dominance over the activated pain circuitry.
TTE Elephant's occipital ridge protocol targets the same anatomical pathways — the greater occipital nerve (GON) and its convergence with vagal afferents at the trigeminocervical complex (C1–C3) — through mechanically mediated pressure and sustained compression. The absence of a device does not change the neuroanatomical target; it changes the stimulus modality.
The Trigeminovascular System and Scalp Therapy
During a migraine attack, the trigeminovascular pathway amplifies pain through central sensitisation. The trigeminal nucleus caudalis, located in the upper cervical spinal cord, receives convergent input from both the meninges and the scalp. This is why scalp allodynia — the phenomenon where the scalp becomes painful to touch during attacks — affects approximately 70% of migraine patients.
This convergence is also the therapeutic entry point. Reducing peripheral nociceptive input from the scalp and occipital region decreases the afferent load reaching the trigeminal nucleus, partially interrupting the central sensitisation feedback loop.
Temporal Pressure Release and the Myofascial Component
Tension-type headache and migrainous headache frequently co-occur. The temporalis muscle — which spans the lateral skull from the temporal bone to the mandible — is among the most commonly hypertonic muscles in headache patients. Prolonged screen use, jaw clenching, and forward head posture all increase temporalis tone.
TTE's temporal region massage targets the temporalis fascia directly, releasing myofascial tension that contributes to the compressive, vice-like quality of tension-type headache and can lower the threshold for migrainous episodes.
The Sleep-Migraine Bidirectionality
Poor sleep lowers the migraine threshold via orexin and serotonin dysregulation. Migraines, conversely, fragment sleep architecture — reducing slow-wave sleep and REM continuity. This bidirectionality creates a self-reinforcing cycle that OTC analgesics cannot address.
TTE's Sleep Healing Headspa protocol targets both vectors: delta wave induction through low-frequency scalp vibration restores slow-wave sleep architecture, while the vagal stimulation components reduce the sympathetic arousal state that primes migraine attacks.
Who Benefits Most
- Clients with tension-type headache (cervicogenic, temporalis-driven): most direct benefit
- Clients with chronic migraine and high allodynia: strong preventive benefit via central sensitisation modulation
- Clients in the prodrome phase: gentle vagal stimulation may interrupt the attack before full onset
- Clients with sleep-migraine bidirectionality: dual intervention via Sleep Healing protocol
FAQ
Q: Is head spa an acute migraine treatment? A: For tension-type and cervicogenic headache, scalp therapy can provide acute relief. For classic vascular migraine, head spa therapy is most effective as a preventive intervention — reducing attack frequency and severity through regular vagal stimulation and central sensitisation modulation. Treatment during peak allodynia (when the scalp is painful to touch) is not recommended.
Q: What is gammaCore and how does TTE's protocol relate to it? A: gammaCore is an FDA-approved handheld device that delivers electrical stimulation to the cervical vagus nerve. TTE's occipital ridge protocol stimulates convergent vagal pathways via the greater occipital nerve through mechanical pressure — the same anatomical target, different modality. Both activate the locus coeruleus noradrenergic pathway to suppress CGRP release.
Q: How many sessions before migraine frequency reduces? A: Clinical nVNS studies show statistically significant reductions in migraine days at 4–8 weeks of consistent treatment. Based on this model, we recommend a minimum of 4 sessions before assessing frequency changes. Clients with high stress load or poor sleep may require concurrent lifestyle modification for full effect.
Q: Can scalp allodynia be treated? A: Scalp allodynia reflects central sensitisation — the pain system has been recalibrated to respond to normally non-painful stimuli. It cannot be resolved acutely. Over time, consistent reduction of the afferent pain load (through vagal stimulation, occipital nerve work, and stress reduction) progressively raises the allodynia threshold.
Q: Does CGRP explain why stress causes both scalp problems and migraines? A: Precisely. Under stress, the HPA axis elevates cortisol, which primes sympathetic nervous system activity and lowers the threshold for CGRP release from both trigeminal terminals (migraine) and scalp sensory nerve fibres (neurogenic scalp inflammation, itch). The scalp and the migraine pathway share this upstream trigger — which is why nervous system regulation is a genuine therapeutic target for both.
